Fibroblast growth factor receptor
Showing 1 - 25 of >10,000
Bladder Transitional Cell Carcinoma, Bladder Cancer, Fibroblast Growth Factor Receptor Trial (Infigratinib)
Withdrawn
- Bladder Transitional Cell Carcinoma
- +2 more
- (no location specified)
Aug 8, 2022
Urothelial Carcinoma Trial in Shanghai (AZD4547, Tislelizumab)
Recruiting
- Urothelial Carcinoma
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Mar 8, 2023
Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Sarcoma, Metastatic Gastrointestinal Stromal Tumor Trial in
Recruiting
- Locally Advanced Gastrointestinal Stromal Tumor
- +7 more
- Biopsy
- +4 more
-
Duarte, California
- +17 more
Feb 2, 2023
Advanced or Recurrent Solid Tumors, FGFR Gene Alterations Trial in Japan (E7090)
Recruiting
- Advanced or Recurrent Solid Tumors
- FGFR Gene Alterations
-
Aoba-ku, Sendai, Miyagi, Japan
- +4 more
May 9, 2022
Squamous-cell NSCLC Trial in Switzerland (Rogaratinib)
Active, not recruiting
- Squamous-cell Non-small Cell Lung Cancer
-
Baden, Switzerland
- +10 more
Jan 20, 2022
Metastatic Breast Cancer, FGFR 1 High Amplification, FGFR2 Amplification Trial in Worldwide (Futibatinib, Futibatinib plus
Recruiting
- Metastatic Breast Cancer
- +2 more
- Futibatinib
- Futibatinib plus Fulvestrant
-
Phoenix, Arizona
- +36 more
Jan 27, 2023
Advanced or Metastatic Solid Tumor Trial in Worldwide (Rogaratinib (BAY1163877), Copanlisib (BAY80-6946))
Completed
- Advanced or Metastatic Solid Tumor
- Rogaratinib (BAY1163877)
- Copanlisib (BAY80-6946)
-
Los Angeles, California
- +19 more
Jul 13, 2022
Squamous-Cell Non-Small-Cell Lung Cancer Trial in Worldwide (Bemarituzumab, Docetaxel)
Recruiting
- Squamous-Cell Non-Small-Cell Lung Cancer
-
Orange, California
- +24 more
Jul 27, 2022
Serum Fibroblast Growth Factor-21 Levels During Prolonged
Completed
- Fibroblast Growth Factor-21
- Fasting
- 12 hour fasting for 29 days
-
Ankara, TurkeyHacettepe University Nutrition and Dietetics Department
Mar 29, 2023
Tumors Trial in Worldwide (Rogaratinib (BAY1163877) oral solution, Rogaratinib (BAY1163877) oral tablet, Rogaratinib
Completed
- Neoplasms
- Rogaratinib (BAY1163877) oral solution
- +2 more
-
Chicago, Illinois
- +28 more
Apr 12, 2021
Fibroblast Growth Factor 21, Tast Perference Trial (Fibroblast growth factor 21 infusion, Placebo infusion (saline))
Active, not recruiting
- Fibroblast Growth Factor 21
- Tast Perference
- Fibroblast growth factor 21 infusion
- Placebo infusion (saline)
-
Hellerup, DenmarkAmalie R Lanng
Nov 21, 2022
Fibrous Dysplasia Of Bone Trial run by the National Institute of Dental and Craniofacial Research (NIDCR) (Burosumab)
Not yet recruiting
- Fibrous Dysplasia Of Bone
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 24, 2022
Fibroblast Growth Factor 23 and Sclerostin in Relation to
Not yet recruiting
- COVID-19
- Calcium
- +3 more
-
Aswan, EgyptAswan University hospital
Mar 11, 2022
Recurrent Glioblastoma Trial (Targeted Epidermal Growth Factor Receptor Variant III(EGFRvIII) autochimeric antigen receptor T
Not yet recruiting
- Recurrent Glioblastoma
- Targeted Epidermal Growth Factor Receptor Variant III(EGFRvIII) autochimeric antigen receptor T cell injection
- (no location specified)
Apr 4, 2023
NAFLD Trial in Ahvaz (Soy isoflavone, Placebo)
Completed
- NAFLD
- Soy isoflavone
- Placebo
-
Ahvaz, Khuzestan, Iran, Islamic Republic ofAsal Neshatbini Tehrani
Oct 24, 2023
Healthy Trial in Frederiksberg (Sucrose, Sucrose + protein, Sucrose + fat)
Completed
- Healthy
- Sucrose
- +2 more
-
Frederiksberg, DenmarkDepartment of Nutrition, Exercise and Sports, University of Cope
Mar 30, 2022
Fibroblast Growth Factor 23 in Chronic Respiratory Failure
Not yet recruiting
- Chronic Respiratory Failure
- Dosage
- Cardiac echography
- (no location specified)
Feb 17, 2022
NSCLC (NSCLC) Trial (Osimertinib, Amivantamab)
Not yet recruiting
- Non-Small Cell Lung Cancer (NSCLC)
- (no location specified)
Mar 24, 2023
Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations Trial in
Recruiting
- Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
-
Canton, OhioGabrail Cancer and Research Center
Jul 21, 2023